BACKGROUND: In carcinogenesis, methylation of DNA promoter regions results in inactivation of tumor-suppressing genes.
MG98 was designed to inhibit DNA methyltransferases enzyme 1 production.
METHODS: This multicenter study explored two schedules of MG98 with Interferon-α-2β to identify schedule and dose for patients with metastatic RCC.
RESULTS: Doses of IFN 9 MIU/MG98 125 mg/m2 for a continuous schedule and IFN 9 MIU/MG98 200 mg/m2 for an intermittent schedule were considered the MTDs. Treatment resulted in one PR and eight SD.
CONCLUSION: MG98 combined with IFN was safe and resulted in clinical activity.
Written by:
Amato RJ, Stephenson J, Hotte S, Nemunaitis J, Bélanger K, Reid G, Martell RE. Are you the author?
Department of Internal Medicine, The University of Texas Medical School/ Memorial Hermann Cancer Center, Houston, Texas 77030, USA.
Reference: Cancer Invest. 2012 Jun;30(5):415-21.
doi: 10.3109/07357907.2012.675381
PubMed Abstract
PMID: 22571342
UroToday.com Investigative Urology Section
